Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer

Shurbaji, Muhammad S.; Kalbfleisch, John H.; Thurmond, T. Scott

doi:10.1016/0046-8177(95)90122-1

Cited by 77 publications

(42 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study analyzed the expression of GADD45A and p53 by immunohistochemistry. The mutant p53 protein is more stable than the wild-type protein and can be detected by immunohistology (16). The immunoreactivity of p53 can be used as a measure of the loss of normal p53 function (13).…”

Section: Discussionmentioning

confidence: 99%

GADD45A expression is correlated with patient prognosis in esophageal cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. The prognosis of patients with esophageal cancer remains poor, and the tumor-node-metastasis classification system is not sufficient for predicting patient prognoses. Therefore, the identification of novel predictive markers for esophageal cancer is required. The present study investigated the clinicopathological significance of growth arrest and DNA damage-inducible 45α (GADD45A) and p53 in resectable esophageal squamous cell carcinoma (ESCC). The study consisted of 62 patients with esophageal cancer who underwent surgery between 2001 and 2007. The expression of the GADD45A gene product (GADD45A) and the p53 protein was analyzed by immunohistochemistry. The correlations among GADD45A expression, clinicopathological factors and prognosis were then analyzed in the patients with ESCC. GADD45A and p53 were expressed in 56.5% (35/62) and 48.4% (30/62) of patients, respectively. The expression of GADD45A did not show a marked correlation with that of p53. However, GADD45A expression correlated with pathological stage (stage 0-I vs. stages II-IV; P=0.014) and did not correlate with the tumor (T) or node (N) status. Furthermore, patients who were positive for GADD45A exhibited a significantly higher survival rate than those who were negative for GADD45A (log-rank test, P=0.009). Multivariate analysis indicated that T status, N status and GADD45A expression were significant variables predicting survival (hazard ratio, 2.486; 95% confidence interval, 1.168-5.290; P=0.018). Overall, GADD45A expression significantly affected the survival of patients with ESCC, and the reduced expression of GADD45A was correlated with a poor prognosis following curative surgery in these patients. IntroductionThe prognosis of esophageal cancer patients remains poor, emphasizing the requirement for the development of novel treatment strategies. At present, the overall 5-year survival rate is <50%, despite the use of multimodality therapies. Numerous patients, even those with early-stage disease, develop local recurrence of tumors or distant metastasis within a short time period after surgery. To develop novel treatment strategies, it is important to understand the biological behavior of esophageal cancer. Recent studies have found that a number of genes and molecules show involvement in the origin and/or progression of esophageal cancer, including tumor protein p53 (1), deleted in esophageal cancer 1 (2), deleted in colorectal cancer (3), deleted in lung cancer 1 (4), cyclin D1 (5), adenomatous polyposis coli (6) and survivin (7). However, the exact mechanisms underlying esophageal squamous cell carcinoma (ESCC) development and progression remain unclear.The p53 gene is required for the proper induction of the G 1 checkpoint and functions to upregulate growth arrest and DNA damage-inducible 45α (GADD45A) and WAF1/p21 expression (8). Additionally, GADD45A is a downstream mediator of p53 and is able to deactivate p53, thereby contributing to cell cycle regulation through binding with cyclin-dependent kinases and proliferating cell nuc...

show abstract

Section: Discussionmentioning

confidence: 99%

GADD45A expression is correlated with patient prognosis in esophageal cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the study by MildeLangosch et al, (1995) on vulvar cancer, loss of p53 function was associated with a high risk of progression and an unfavourable prognosis. In the literature the prognostic value of p53 seems to be controversial, because in some studies p53 is considered prognostic relevant (Charpin et al, 1995;Esrig et al, 1994;Florenes et al, 1994;Shurbaji et al, 1995;Sun et al, 1992;Vogt et al, 1997), whereas in other studies it is not King et al, 1996;Ofner et al, 1995;Xerri et al, 1994;Younes et al, 1995). It may be that the prognostic value of p53 depends on whether mutation of p53 occurs during carcinogenesis, progression or metastasis of the tumour.…”

Section: Discussionmentioning

confidence: 99%

“…Genetic alteration of this gene is associated with prognostic relevance in several tumours (Charpin et al, 1995;Esrig et al, 1994;Florenes et al, 1994;Shurbaji et al, 1995;Sun et al, 1992;Vogt et al, 1997), including vulvar carcinomas (Kohlberger et al, 1995;Milde-Langosch et al, 1995). It has been shown that cells defective for the p53 gene continue to enter the S phase after irradiation with an increased chance for aberrant DNA to be duplicated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases

et al. 1999

View full text Add to dashboard Cite

SummaryTo offer more tailored treatment to individual patients with squamous cell carcinoma of the vulva, more accurate prediction of lymph node metastases is required. As p53 and mdm2 are genes known to be involved in the development of other tumours, we studied expression of p53 and mdm2 in carcinogenesis of squamous cell carcinoma of the vulva and their clinical relevance. Archival material of 141 T1 and T2 vulvar tumours were used. Of the 141 primary tumours, the corresponding 39 lymph node metastases (LNM) were studied, and in 90 cases the pre-existent epithelia adjacent to the tumour (EAT) and in 14 cases vulvar intraepithelial neoplasia adjacent to the tumour (VIN) was also investigated. Detection of p53 and mdm2 protein was immunohistochemically performed. Scoring categories were: negative (1); weakly positive (2); moderately to markedly positive (3); and markedly positive (4). Overexpression of p53 was seen in 56% of the LNM, 39% of the primary tumours, 21% of the VIN lesions and 0% in the group of EAT. No relation was found between overexpression of p53 in the primary tumour and LNM. Expression of mdm2 was seen in 14% of the primary tumours, of which four cases were marked positive. In the group of LNM no mdm2-positive staining was observed. In the group of EAT, 25% was mdm2-positive, of which six cases were marked positive. In the group of VIN, 36% showed moderate (score 3) mdm2 expression. No relation was found between expression of mdm2 and LNM. In squamous cell carcinoma, overexpression of p53 is a late event in carcinogenesis. Marked expression of mdm2 is rarely seen in vulvar carcinomas, indicating that aberrant p53 cannot induce mdm2 expression. LNM cannot be predicted by detection of these proteins.

show abstract

“…In this way, p53 immunoreactivity is likely to reflect p53 gene mutations (Papadopoulos et al, 1996). Numerous studies suggested the role of p53 mutation in the pathogenesis of prostate cancer, even if recent studies reported conflicting results about the incidence of nuclear p53 accumulation (Samaan et al, 1993;Kallakury et al, 1994;Fox et al, 1993;Shurbaji et al, 1995).…”

mentioning

confidence: 99%

Biological aggressiveness evaluation in prostate carcinomas: immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas

Cappello

Palma²,

Martorana³

et al. 2009

Eur J Histochem

View full text Add to dashboard Cite

We selected 63 prostate tumors with Gleason's grade 6 (3+3), commonly showing both tubular and cribrous patterns. We compared in both patterns the expression of two of the most used biologic markers: PCNA and p53, with the aim to verify the validity of the Gleason's grading system to compare the morphologic grade with biologic aggressiveness and prognostic value. We did not find any statistical difference in the protein immunopositivity, indicating that both patterns could have identical biologic behaviour; then we confirmed the validity of Gleason's system for considering both tubular and cribrous patterns as an intermediate grade of tumoral differentiation. Moreover, we found a linear relationship between the increase of PCNA and the accumulation of mutated p53; this datum could confirm the hypothesis that p53 mutation is a late event in prostate carcinogenesis.

show abstract

Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer

Cited by 77 publications

References 9 publications

GADD45A expression is correlated with patient prognosis in esophageal cancer

GADD45A expression is correlated with patient prognosis in esophageal cancer

In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases

Biological aggressiveness evaluation in prostate carcinomas: immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas

Contact Info

Product

Resources

About